**A global investment case for hepatitis C elimination**

Nick Scott\(^1,2\), Christian Kuschel\(^3\), Alisa Pedrana\(^1,2\), Sophia Schroeder\(^1\), Jessica Howell\(^1,2,3,4\), Alexander Thompson\(^3,4\), David Wilson\(^*1,2\), Margaret Hellard\(^*1,2,5,6\)

1 Burnet Institute, Australia; 2 Monash University, Australia; 3 The University of Melbourne, Australia; 4 St Vincent’s Hospital Melbourne, Australia; 5 The Alfred and Monash University, Australia; 6 Peter Doherty Institute for Infection and Immunity, Australia

**AIMS**

To help catalyze financing for hepatitis C elimination, we developed a global investment case.

For the first time, we considered both direct and indirect economic benefits.

**COST OF ELIMINATION**

Globally, the elimination scenario had:

- A total cost of US$51.0 billion (US$42.1-60.0 billion), 2018-2030
- A peak annual cost of US$5.7 billion (US$4.8-6.6 billion) in 2021
- BUT, the annual direct costs became less than in the scenario of inaction by 2030.

**RETURN ON INVESTMENT**

Greater initial investment led to greater returns. The hepatitis C elimination scenario:

- Became cost-saving by 2027 due to large productivity gains
- Produced a net US$19.4 billion (US$4.4-33.1 billion) return globally by 2030

**METHODS**

Mathematical and economic modelling was used to project two scenarios:

1) **Elimination**: scaling up testing and treatment to reach the WHO targets of 90% of people living with hepatitis C diagnosed and 80% of people diagnosed started on treatment.

2) **Progress**: scaling up testing and treatment to reach the WHO targets of 90% of people living with hepatitis C diagnosed and 80% of people diagnosed started on treatment.

Independent models were calibrated for the six WHO world regions, and a productivity model was used to capture hepatitis C-attributable productivity losses due to absenteeism and presenteeism.

**EPIDEMIOLOGICAL AND HEALTH IMPACT OF ELIMINATION**

Between 2018-2030, the elimination scenario was estimated to:

- Prevent 2.1 (1.2-3.1) million hepatitis C-related deaths
- Prevent 12 (9-19) million new hepatitis C infections
- Substantially reduce the number of people with hepatitis C

---

**Graphs and Tables**

- Estimated annual direct hepatitis C costs globally
- Net economic benefit of hepatitis C investment scenarios
- Total people living with hepatitis C, by WHO region
- Total hepatitis C incidence, by investment strategy
- Total hepatitis C-related deaths, by investment strategy